Literature DB >> 25891084

Diltiazem augments the influence of MDR1 genotype status on cyclosporine concentration in Chinese patients with renal transplantation.

Yi-xi Wang1, Jia-li Li2, Xue-ding Wang2, Yu Zhang2, Chang-xi Wang3, Min Huang2.   

Abstract

AIM: Co-administration of diltiazem can reduce the dosage of cyclosporine (CsA) in patients with renal transplantation. In this study, we investigated how diltiazem altered the relationship between MDR1 genetic polymorphisms and CsA concentration in Chinese patients with renal transplantation.
METHODS: A total of 126 renal transplant patients were enrolled. All the patients received CsA (2-4 mg·kg(-1)·d(-1)), and diltiazem (90 mg/d) was co-administered to 76 patients. MDR1-C1236T, G2677T/A, and C3435T polymorphisms were genotyped. The whole blood concentration was measured using the FPIA method, and the adjusted trough concentrations were compared among the groups with different genotypes.
RESULTS: In all patients, MDR1-C1236T did not influence the adjusted CsA trough concentration. With regard to MDR1-3435, the adjusted CsA trough concentration was significantly higher in TT carriers than in CC and CT carriers when diltiazam was co-administered (58.83±13.95 versus 46.14±7.55 and 45.18±12.35 ng/mL per mg/kg, P=0.011), and the differences were not observed in patients without diltiazam co-administered. With regard to MDR1-2677, the adjusted CsA trough concentration was significantly higher in TT carriers than in GG and GT carriers when diltiazam was co-administered (61.31±12.93 versus 52.25±7.83 and 39.70±7.26 ng/mL per mg/kg, P=0.0001). The differences were also observed in patients without diltiazam co-administered (43.27±5.95 versus 35.22±7.55 and 29.54±5.35 ng/mL per mg/kg, P=0.001). The adjusted CsA trough blood concentration was significantly higher in haplotype T-T-T and haplotype T-T-C carriers than in non-carriers, regardless of diltiazem co-administered.
CONCLUSION: MDR1 variants influence the adjusted CsA trough concentration in Chinese patients with renal transplant, and the influence more prominent when diltiazem is co-administered.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25891084      PMCID: PMC4648117          DOI: 10.1038/aps.2015.6

Source DB:  PubMed          Journal:  Acta Pharmacol Sin        ISSN: 1671-4083            Impact factor:   6.150


  30 in total

1.  Measurement of cyclosporin A in whole blood by RIA, EMIT and FPIA: a comparative study.

Authors:  R Wacke; B Drewelow; E M Hehl; A K Riethling
Journal:  Int J Clin Pharmacol Ther Toxicol       Date:  1992-11

2.  The effect of MDR1 (ABCB1) polymorphism on the pharmacokinetic of tacrolimus in Turkish renal transplant recipients.

Authors:  S H Akbas; T Bilgen; I Keser; M Tuncer; L Yucetin; O Tosun; M Gultekin; G Luleci
Journal:  Transplant Proc       Date:  2006-06       Impact factor: 1.066

3.  Study of neoral kinetics in adult renal transplantation treated with diltiazem.

Authors:  S Mezzano; C Flores; L Ardiles; A Foradori; A Elberg
Journal:  Transplant Proc       Date:  1998-08       Impact factor: 1.066

4.  A general method for isolation of high molecular weight DNA from eukaryotes.

Authors:  N Blin; D W Stafford
Journal:  Nucleic Acids Res       Date:  1976-09       Impact factor: 16.971

5.  The effect of food and bile acid administration on the relative bioavailability of cyclosporin.

Authors:  A Lindholm; S Henricsson; R Dahlqvist
Journal:  Br J Clin Pharmacol       Date:  1990-05       Impact factor: 4.335

6.  MDR1 haplotypes derived from exons 21 and 26 do not affect the steady-state pharmacokinetics of tacrolimus in renal transplant patients.

Authors:  Ingrid Mai; Elke S Perloff; Steffen Bauer; Mark Goldammer; Andreas Johne; Guido Filler; Klemens Budde; Ivar Roots
Journal:  Br J Clin Pharmacol       Date:  2004-11       Impact factor: 4.335

7.  Single nucleotide polymorphisms in the multidrug resistance 1 gene in Korean epileptics.

Authors:  Young Ok Kim; Myeong Kyu Kim; Young Jong Woo; Min Cheol Lee; Jin Hee Kim; Ki Won Park; Eun Young Kim; Young Il Roh; Chan Jong Kim
Journal:  Seizure       Date:  2006-01       Impact factor: 3.184

8.  Role of intestinal P-glycoprotein (mdr1) in interpatient variation in the oral bioavailability of cyclosporine.

Authors:  K S Lown; R R Mayo; A B Leichtman; H L Hsiao; D K Turgeon; P Schmiedlin-Ren; M B Brown; W Guo; S J Rossi; L Z Benet; P B Watkins
Journal:  Clin Pharmacol Ther       Date:  1997-09       Impact factor: 6.875

9.  Diltiazem increases blood concentrations of cyclized cyclosporine metabolites resulting in different cyclosporine metabolite patterns in stable male and female renal allograft recipients.

Authors:  J S Bleck; C Thiesemann; V Kliem; U Christians; H Hecker; H Repp; U Frei; M Westhoff-Bleck; M Manns; K F Sewing
Journal:  Br J Clin Pharmacol       Date:  1996-06       Impact factor: 4.335

10.  Absence of the mdr1a P-Glycoprotein in mice affects tissue distribution and pharmacokinetics of dexamethasone, digoxin, and cyclosporin A.

Authors:  A H Schinkel; E Wagenaar; L van Deemter; C A Mol; P Borst
Journal:  J Clin Invest       Date:  1995-10       Impact factor: 14.808

View more
  2 in total

1.  Population Pharmacokinetic Modeling of Diltiazem in Chinese Renal Transplant Recipients.

Authors:  Xiao-Feng Guan; Dai-Yang Li; Wen-Jun Yin; Jun-Jie Ding; Ling-Yun Zhou; Jiang-Lin Wang; Rong-Rong Ma; Xiao-Cong Zuo
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2018-02       Impact factor: 2.441

Review 2.  Drug-drug-gene interactions and adverse drug reactions.

Authors:  Mustafa Adnan Malki; Ewan Robert Pearson
Journal:  Pharmacogenomics J       Date:  2019-12-03       Impact factor: 3.550

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.